U.S. Markets closed

BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know

Zacks Equity Research
Eagle Bancorp (EGBN) delivered earnings and revenue surprises of -4.43% and -0.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) closed at $47.69 in the latest trading session, marking a +1.6% move from the prior day. This change outpaced the S&P 500's 0.21% gain on the day. Meanwhile, the Dow gained 0.17%, and the Nasdaq, a tech-heavy index, added 0.27%.

Coming into today, shares of the heart monitoring device maker had lost 11.53% in the past month. In that same time, the Medical sector lost 1.96%, while the S&P 500 lost 5.26%.

Investors will be hoping for strength from BEAT as it approaches its next earnings release. The company is expected to report EPS of $0.45, down 2.17% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $111.08 million, up 9.59% from the year-ago period.

BEAT's full-year Zacks Consensus Estimates are calling for earnings of $1.90 per share and revenue of $446.22 million. These results would represent year-over-year changes of -2.06% and +11.7%, respectively.

Investors might also notice recent changes to analyst estimates for BEAT. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.52% lower. BEAT is currently a Zacks Rank #4 (Sell).

Digging into valuation, BEAT currently has a Forward P/E ratio of 24.7. This represents a premium compared to its industry's average Forward P/E of 19.89.

The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BioTelemetry, Inc. (BEAT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.